Amgen, Inc.

Amgen, Inc. logo
🇺🇸United States
Ownership
Public
Established
1980-01-01
Employees
26.7K
Market Cap
$175.6B
Website
http://www.amgen.com
Clinical Trials
Related News

An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density

Phase 3
Completed
Conditions
Low Bone Mineral Density
Interventions
Drug: AMG 162
First Posted Date
2006-05-12
Last Posted Date
2017-08-01
Lead Sponsor
Amgen
Target Recruit Count
200
Registration Number
NCT00325468

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

First Posted Date
2006-05-05
Last Posted Date
2013-07-31
Lead Sponsor
Amgen
Target Recruit Count
46
Registration Number
NCT00322400

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

Phase 3
Completed
Conditions
Bone Metastases
Interventions
Drug: zoledronic acid
Biological: denosumab
First Posted Date
2006-05-04
Last Posted Date
2018-08-29
Lead Sponsor
Amgen
Target Recruit Count
1904
Registration Number
NCT00321620

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Phase 3
Completed
Conditions
Bone Metastases
Interventions
Biological: Denosumab
Drug: Zoledronic Acid
First Posted Date
2006-05-03
Last Posted Date
2022-11-08
Lead Sponsor
Amgen
Target Recruit Count
2049
Registration Number
NCT00321464

A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma

First Posted Date
2006-01-30
Last Posted Date
2011-06-20
Lead Sponsor
Amgen
Target Recruit Count
39
Registration Number
NCT00283439

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

First Posted Date
2006-01-16
Last Posted Date
2010-10-08
Lead Sponsor
Amgen
Target Recruit Count
852
Registration Number
NCT00277160

ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: Aranesp
Drug: Neulasta
First Posted Date
2005-12-05
Last Posted Date
2010-02-26
Lead Sponsor
Amgen
Target Recruit Count
80
Registration Number
NCT00261313

Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab

Phase 2
Completed
Conditions
Relapsed or Plateau-Phase Multiple Myeloma
Interventions
Drug: DENOSUMAB
First Posted Date
2005-12-01
Last Posted Date
2017-03-15
Lead Sponsor
Amgen
Target Recruit Count
96
Registration Number
NCT00259740

Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors

Phase 2
Completed
Conditions
Advanced Gastrointestinal Stromal Tumor
Interventions
Drug: AMG 706
First Posted Date
2005-11-16
Last Posted Date
2014-02-27
Lead Sponsor
Amgen
Target Recruit Count
35
Registration Number
NCT00254267

EPO Deep Tank in Dialysis Subjects

Phase 3
Completed
Conditions
Chronic Kidney Disease
Interventions
Drug: Epoetin alfa DT
First Posted Date
2005-09-12
Last Posted Date
2010-02-19
Lead Sponsor
Amgen
Target Recruit Count
580
Registration Number
NCT00156949
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy